RLAY stock forecast, quote, news & analysis
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients... Show more
Why Relay Therapeutics (RLAY) Is Up +69% in the Last 30 Days
Key Takeaways
- RLAY stock surged +69% over the past 30 days, propelled by positive clinical data updates on its lead candidate zovegalisib.
- Over the past quarter, shares climbed +122%, supported by an earnings beat and advancing pipeline milestones.
- Key drivers include expansions of zovegalisib into new indications like vascular anomalies and oncology data presentations.
- Analyst coverage initiated with Hold ratings but optimistic price targets around $18, reflecting pipeline potential.
- Biotech sector sentiment and clinical progress outweighed macroeconomic pressures on small-cap precision medicine stocks.
Relay Therapeutics (RLAY) Company Overview and Market Position
Relay Therapeutics, Inc. (RLAY) is a clinical-stage precision medicines company leveraging its proprietary Dynamo platform to design and develop small molecule therapeutics for targeted oncology and genetic diseases. The platform integrates computational and experimental approaches to target challenging protein structures, enabling novel drug candidates. Its lead program, zovegalisib (RLY-2608), a PI3Kα (phosphoinositide 3-kinase alpha) inhibitor, targets breast cancer, solid tumors, and vascular malformations. Other candidates include RLY-4008 and programs for Fabry disease and RAS( G12C) mutations. In the competitive precision oncology space, Relay differentiates through its physics-based drug discovery, positioning it amid peers like Turning Point Therapeutics and Revolution Medicines. Strong fundamentals in clinical data have driven recent stock price appreciation amid biotech volatility.
Relay Therapeutics (RLAY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RLAY stock rose +69%, from approximately $9.91 to $16.76. The movement was volatile and trend-driven, with sharp surges on clinical news, including multi-day gains exceeding 30% in early April, punctuated by consolidation periods.
In the past quarter, shares advanced +122%, from around $7.54 to $16.76. The trajectory featured a steady climb with acceleration points tied to catalysts, transitioning from range-bound early in the period to a pronounced uptrend, reflecting heightened investor interest.
What Drove RLAY Stock Price in the Last 30 Days
The 30-day rally was dominated by clinical advancements in the zovegalisib program. On April 2, Relay announced Phase 1/2 data for zovegalisib combined with fulvestrant at the Phase 3 dose, presented at the ESMO Targeted Anticancer Therapies Congress, sparking initial gains. This was followed by expansion into vascular anomalies, with initial clinical data shared ahead of the International Society for the Study of Vascular Anomalies World Congress, leading to a 30.6% jump. Shares surged 16.4% on April 6 amid anticipation of cancer treatment updates and 16% climbs on further disclosures. Analyst initiations, including a Hold from JonesResearch with an $18 target, added support. Positive sentiment shifts in biotech, bolstered by high trading volumes, amplified these company-specific catalysts, propelling the stock price upward.
What Drove RLAY Stock Performance Over the Last Quarter
The quarter's +122% gain stemmed from sustained pipeline momentum and financial results. Q4 2025 earnings on February 26 reported a narrower-than-expected loss of $0.32 per share versus consensus of -$0.38, boosting confidence. Subsequent zovegalisib data readouts, including oncology combinations, built on this, with March surges like 5.4% on March 11. Institutional accumulation, highlighted by funds increasing stakes to $110 million, signaled conviction. Broader biotech recovery amid stabilizing interest rates and oncology demand favored RLAY's precision focus. Competitive positioning strengthened via collaborations with Pfizer and others, while regulatory tailwinds in targeted therapies had the strongest cumulative impact, driving the robust quarterly uptrend.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms trading thousands of tickers across various markets. These curated bots represent the most relevant and high-achieving strategies based on recent performance metrics like win rate, profit factor, and Sharpe ratio. Strategies range from momentum and mean reversion to pattern recognition, spanning short-term day trades to longer-term swings. Investors can explore detailed backtests, live results, and customization options. Check out the Trending AI Robots page to discover bots potentially suited for your RLAY stock analysis and portfolio strategy.
RLAY Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming milestones in the zovegalisib program, including initial clinical data on approximately 20 efficacy-evaluable patients in vascular anomalies, slated for late May. Q1 2026 earnings around early May will provide updates on cash runway—currently supporting operations into 2028—and pipeline progress. Industry trends in PI3K inhibitors and precision oncology M&A (mergers and acquisitions) activity could influence sentiment. Macro factors like interest rates and biotech funding environment remain key. Risks include clinical trial setbacks, while catalysts encompass additional data readouts, partnerships, or regulatory designations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
RLAY in upward trend: 10-day moving average broke above 50-day moving average on May 21, 2026
The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on May 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on June 11, 2026. You may want to consider a long position or call options on RLAY as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on June 12, 2026. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
RLAY moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for RLAY moved out of overbought territory on June 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RLAY broke above its upper Bollinger Band on June 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLAY entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.025) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). RLAY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (243.902) is also within normal values, averaging (357.550).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets
Industry Biotechnology